-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Proton shares announced that in order to meet the rapid growth of preclinical and early clinical (CRO) business development needs, the company plans to acquire 100% equity of Kaihui Pharmaceutical held by Ruizhi Chemical at a price of RMB 266 million in cash.
.
After the completion of this transaction, the company will hold 100% equity of Kaihui Pharmaceutical, and Kaihui Pharmaceutical will become a wholly-owned subsidiary of the company and will be included in the scope of the company's consolidated financial statements
.
It is understood that industrial chain extension or product line expansion through investment, acquisition, etc.
has become very common in the pharmaceutical field
.
Recently, in addition to Proton shares, many companies are buying and buying to further enhance the competitiveness and comprehensive strength of some of their businesses
.
As not long ago, Haoyuan Pharmaceutical plans to win the drug source drug with 400 million yuan to realize another acquisition after the listing
.
According to the announcement of Haoyuan Pharmaceutical, the company plans to issue shares and pay cash to WANG YUAN (Wang Yuan), Shanghai Yuanmeng, Qidong Yuanli, and Ningbo Jiusheng to purchase 100% equity of Yaoyuan Medicine held by them.
The transaction price is not expected to exceed 420 million yuan
.
Yaoyuan Pharmaceutical, the target company to be acquired this time, is a high-tech enterprise that provides one-stop services for pharmaceutical R&D, registration and production of APIs and preparations for new drug developers, especially in the field of preparation CMC business
.
It is reported that in the past, Haoyuan Pharmaceutical’s expansion in the back-end of research and development was basically limited to the API and intermediate business.
This acquisition is expected to continue to extend the Haoyuan Pharmaceutical service chain, make up for shortcomings, and create an “intermediate-API-formulation”.
"Integrated CRO/CDMO/CMO whole industry service platform
.
On February 8, CSPC announced that it has completed the acquisition of 100% equity of Zhuhai Zhifan Enterprise Management Consulting Center
.
The main business of Zhuhai Zhifan is to invest in Mingkang Bio, and it holds a registered capital of Mingkang Biology of RMB94,452,900 (of which RMB32,866,500 has not been paid), accounting for approximately 51% of the total registered capital of Mingkang Biology as at the date of this announcement
.
According to the data, Mingkang Bio is a biotechnology company engaged in the research and development, production and sales of biological drugs.
.
Mingfule (recombinant human TNK tissue plasminogen activator for injection) independently developed by the company is a third-generation specific thrombolytic drug with intellectual property rights.
The treatment of thrombolysis in patients with acute myocardial infarction; its indication for thrombolysis in cerebral infarction was approved for clinical trials in 2017, and a phase III clinical trial (TRACEII) will be launched in 2021
.
CSPC believes that the product has good commercial potential, so the acquisition will further strengthen the group's product pipeline and provide new growth drivers
.
On January 10, Pharmaron announced that it has successfully acquired Aesica Pharmaceuticals (hereinafter referred to as: Cramlington production base) under Recipharm in Cramlington, UK
.
It is understood that the Cramlington production base is located in Newcastle, UK, with a production capacity of more than 100 cubic meters of reactors, and can provide cGMP API production services from pilot to ton commercial scale
.
The production facility has been inspected and certified by various regulatory agencies, including the U.
S.
Food and Drug Administration (FDA)
.
Generally speaking, it has become the norm in the industry for pharmaceutical companies to carry out investment activities and acquire shares and businesses
.
With the rising tide of mergers and acquisitions in the pharmaceutical industry, the industry expects that more and more pharmaceutical companies will also speed up the pace of company development and growth through acquisitions and reorganizations in the future, and help the growth of new drug varieties
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
After the completion of this transaction, the company will hold 100% equity of Kaihui Pharmaceutical, and Kaihui Pharmaceutical will become a wholly-owned subsidiary of the company and will be included in the scope of the company's consolidated financial statements
.
It is understood that industrial chain extension or product line expansion through investment, acquisition, etc.
has become very common in the pharmaceutical field
.
Recently, in addition to Proton shares, many companies are buying and buying to further enhance the competitiveness and comprehensive strength of some of their businesses
.
As not long ago, Haoyuan Pharmaceutical plans to win the drug source drug with 400 million yuan to realize another acquisition after the listing
.
According to the announcement of Haoyuan Pharmaceutical, the company plans to issue shares and pay cash to WANG YUAN (Wang Yuan), Shanghai Yuanmeng, Qidong Yuanli, and Ningbo Jiusheng to purchase 100% equity of Yaoyuan Medicine held by them.
The transaction price is not expected to exceed 420 million yuan
.
Yaoyuan Pharmaceutical, the target company to be acquired this time, is a high-tech enterprise that provides one-stop services for pharmaceutical R&D, registration and production of APIs and preparations for new drug developers, especially in the field of preparation CMC business
.
It is reported that in the past, Haoyuan Pharmaceutical’s expansion in the back-end of research and development was basically limited to the API and intermediate business.
This acquisition is expected to continue to extend the Haoyuan Pharmaceutical service chain, make up for shortcomings, and create an “intermediate-API-formulation”.
"Integrated CRO/CDMO/CMO whole industry service platform
.
On February 8, CSPC announced that it has completed the acquisition of 100% equity of Zhuhai Zhifan Enterprise Management Consulting Center
.
The main business of Zhuhai Zhifan is to invest in Mingkang Bio, and it holds a registered capital of Mingkang Biology of RMB94,452,900 (of which RMB32,866,500 has not been paid), accounting for approximately 51% of the total registered capital of Mingkang Biology as at the date of this announcement
.
According to the data, Mingkang Bio is a biotechnology company engaged in the research and development, production and sales of biological drugs.
.
Mingfule (recombinant human TNK tissue plasminogen activator for injection) independently developed by the company is a third-generation specific thrombolytic drug with intellectual property rights.
The treatment of thrombolysis in patients with acute myocardial infarction; its indication for thrombolysis in cerebral infarction was approved for clinical trials in 2017, and a phase III clinical trial (TRACEII) will be launched in 2021
.
CSPC believes that the product has good commercial potential, so the acquisition will further strengthen the group's product pipeline and provide new growth drivers
.
On January 10, Pharmaron announced that it has successfully acquired Aesica Pharmaceuticals (hereinafter referred to as: Cramlington production base) under Recipharm in Cramlington, UK
.
It is understood that the Cramlington production base is located in Newcastle, UK, with a production capacity of more than 100 cubic meters of reactors, and can provide cGMP API production services from pilot to ton commercial scale
.
The production facility has been inspected and certified by various regulatory agencies, including the U.
S.
Food and Drug Administration (FDA)
.
Generally speaking, it has become the norm in the industry for pharmaceutical companies to carry out investment activities and acquire shares and businesses
.
With the rising tide of mergers and acquisitions in the pharmaceutical industry, the industry expects that more and more pharmaceutical companies will also speed up the pace of company development and growth through acquisitions and reorganizations in the future, and help the growth of new drug varieties
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
